FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, March 10, 2023

Resolving Persistent Spike Protein Syndrome

by Thomas E. Levy, MD, JD

OMNS (March 10, 2023) Editor's Note: Dr. Levy's paper, to follow, is both interesting and important. One might think it is not orthomolecular as such and is not really appropriate for the Orthomolecular Medicine News Service. While I respect that viewpoint, I do not agree. My publication mentor, Dr. Abram Hoffer, taught me by example that physician viewpoints need to be presented for consideration. "Where are the good old days," he wrote, "when honest physicians honestly reported what they saw in language that any doctor could understand?" The NY TIMES used to live by the motto, "All the news that's fit to print." During the heyday of COVID hysteria we saw otherwise. There was considerable bias, even censorship, by legacy media. I do not intend to make that mistake. With nearly 20 years of continuous publication, as long as I am editor, OMNS will stand for open discussion of plausible medical ideas that can save lives. In conjunction, readers should work with their own healthcare providers before making any heath decision. That is common sense. Recognizing the value of a second - or even a third - medical opinion is also common sense. Abram taught me to be inclusive, not exclusive. OMNS will present these ideas. Linus Pauling, who gave orthomolecular medicine its name, said "The best way to have a good idea is to have a lot of ideas." Dr. Pauling, a chemist, was roundly criticized by the medical profession for speaking out on health and nutrition. I am glad he did. - Andrew W. Saul, OMNS Editor-in-Chief

As the acute cases of COVID have continued to decline, the prevalence of the Persistent Spike Protein (PSP) syndrome has continued to increase. The spike protein is that part of the COVID pathogen that attaches to ACE2 receptors throughout the body and permits the entry of the entire virus into the newly infected cell. There appear to be no cells, tissues, or organs in the body that are completely spared from this PSP attack once enough of it has been introduced into the body.

The persistent presence of the spike protein has been shown to be secondary to the inability to completely resolve a bout of COVID (chronic COVID or long-haul COVID) as well as the spike protein exposure from mRNA inoculation(s). And as more time has passed, the PSP syndrome following one or more mRNA shots has emerged as the most common reason for PSP, especially following a booster injection. Not surprisingly, the likelihood of developing a PSP syndrome relates directly to the total amount of spike protein exposure, and the amounts delivered by repeated inoculations substantially exceed the amounts that result from incompletely resolved cases of COVID.

The goal of any therapy designed to eliminate a chronic spike protein presence in the body needs to address its presence in the blood, its presence on the many ACE2 binding sites throughout the body, its presence inside the cells, and the mechanisms that allow it to replicate itself and keep it from being eliminated completely in the body. It has been shown that the sickest of PSP patients have intact spike protein circulating in the blood. [1]

However, eliminating it from the blood does not assure a cure. It is also vital to destroy the cells where the virus and/or spike protein replication is taking place, as well as to destroy any cells that are producing new spike protein because of the presence of the vaccine-supplied mRNA. It remains unclear at the time of this writing whether the cells of tissues or organs not known to regenerate on a regular basis will instead serve as virus/spike protein reservoirs that are not readily accessible to therapeutic agents. Multiple autopsy studies have revealed the presence of spike protein throughout the body, without any particular areas being spared. [2,3]

By itself, the spike protein is also toxic. As all toxins ultimately inflict damage by oxidizing biomolecules needed for normal metabolic function, any effective PSP protocol needs to include significant antioxidative capacity in order to repair damaged (oxidized) biomolecules. Spike protein has been shown to induce inflammation (acute oxidative stress) even without resulting in viral infection. [4]

Bio-Oxidative Therapies

While any therapy that can eradicate an infectious agent must involve its destruction via enhanced oxidation, the most prominent of these therapies involve the appropriate application of:

• Vitamin C (multiple modalities)
• Hydrogen peroxide (multiple modalities)
• Ozone (multiple modalities)
• Ultraviolet blood irradiation
• Hyperbaric oxygen

While still not widely appreciated, these bio-oxidative therapies have been curing acute infectious diseases for very many years now. The resolution of acute viral infections has been especially well-established to result with any of these therapies administered individually or when combined together. All these therapies share the ability to rapidly increase the oxidative stress inside the pathogens themselves and/or the cells that have become infected with the pathogens. Nothing destroys a pathogen or pathogen-infected cell that cannot elevate such oxidative stress to lethal levels. And even though different treatments might have unshared mechanisms in fueling this increased oxidative stress, it is this singular effect that ultimately resolves the infection.

Vitamin C and Hydrogen Peroxide

Vitamin C (VC), interacting directly with extracellular and intracellular hydrogen peroxide (HP) already in the body, works to eradicate pathogens, including the COVID pathogen, by a mechanism known as the Fenton reaction. This reaction produces hydroxyl radical formation in a pathogen or a pathogen-infected cell, which works to oxidize whatever it is next to when it is formed. This ultimately results in the destruction of the pathogen, inside or outside of the cell, when enough VC and HP are present.

Enough HP by itself will also quickly oxidize pathogens and their infected host cells. This can occur with HP nebulization, the direct ingestion of appropriately-dosed HP, and the appropriate infusion of hydrogen peroxide intravenously. Intravenous HP has long been established as a powerful anti-viral agent, curing many of the most critically ill patients in the 1918 influenza pandemic. [5] HP nebulization is especially effective in clearing out areas of chronic pathogen colonization in the nose and throat areas. Even though such areas are usually asymptomatic, they work to keep these "virus-manufacturing" areas of the body much more susceptible to the contraction of new infectious agents, viral or otherwise.

An agent naturally present in the body in large amounts, hydrogen peroxide plays an important role in the pathogen-killing effect of all the bio-oxidative. While the biochemical details of these bio-oxidative therapies remain to be clearly defined, the anti-pathogen effect of HP appears to be an essential part of the final common pro-oxidant pathway in these therapies that is needed to kill the pathogen and clinically resolve the infection.

The nature of the immune system gives further support to the role of both VC and HP in the control and resolution of infections. The monocytes and phagocytes in the immune response are the first cells to appear at new sites of inflammation or infection. Of note, these two types of immune cells have exceptionally high levels of both VC and HP inside them. This results in the immediate delivery of the most important elements of the pathogen-killing Fenton reaction to the new site of infection. [6-10]

Ozone

No agent exceeds the pro-oxidant, pathogen-killing ability of properly-administered ozone. Interestingly, the basic chemical structure of ozone is very close to HP. HP (H2O2) can be regarded as a dioxide of hydrogen, and ozone (O3) can be regarded as a dioxide of oxygen. This dioxide-like structure (two bound oxygens in the molecule) is also present in other molecules with powerful pro-oxidant, pathogen-killing capacity. Chlorine dioxide, nitrogen dioxide, sulfur dioxide, carbon dioxide, titanium dioxide, and silica dioxide have all been shown to have significant anti-pathogen properties. [11-17]

Like HP, ozone has been shown to increase blood oxygen levels and oxygen delivery to the tissues in addition to its anti-pathogen effects. Such an effect can only be expected to further enhance the healing of damaged tissues after the pathogen presence has been eradicated. Furthermore, tumor cells that have been incubated in an ozonated medium have been shown to accumulate HP, supporting the concept that ozone utilizes HP-related mechanisms in its pro-oxidant response involved in cancer cells as well as pathogens. [18] Anything that can increase HP levels in or around a target cell or pathogen greatly facilitates its susceptibility to destruction when the microenvironment triggers the conversion of HP to hydroxyl radical.

Although VC appears to have been much more studied during the pandemic as an anti-COVID agent, there is no evidence to suggest that ozone is not just as effective in destroying the COVID pathogen versus any other pathogen. [19] Furthermore, ozone has been shown to be clearly beneficial while maintaining a high safety profile when used as adjuvant therapy in the treatment of advanced COVID patients. [20-23] Applied early enough in the course of a COVID infection, ozone significantly reduces hospitalization time and improves blood oxygenation. Laboratory markers of coagulation and inflammation are significantly improved with such therapy as well. [24,25]

The PSP (persistent spike protein) syndrome is now affecting literally millions of patients around the world. Some are due to the PSP presence resulting from COVID infection that never really resolves completely. However, many more now appear to be resulting from the COVID shots. Not surprisingly, the likelihood of having PSP syndrome directly correlates to the total amount of spike protein in the body, and every shot supplies more of this toxic protein. Feeling well after the first one or two shots and then deteriorating rapidly following a booster shot is an increasingly common occurrence.

Chronic COVID symptomatology secondary to the PSP syndrome responds very well to oxygen-ozone autohemotherapy. Fatigue remains the singular most common symptom in such PSP patients, even though very many other symptoms can be present as well. In fact, over 50 long-term symptoms from COVID have been reported. [26] In a series of 100 chronic COVID patients suffering prominently with chronic fatigue, one to nine autohemotherapy ozone treatments were administered over a period of up to three weeks. All the patients reported less fatigue, and impaired functionality secondary to chronic fatigue was restored to a normal level in at least two thirds of the patients. [27]

Anecdotal evidence seen with before-and-after dark field examinations on patients with indirect evidence of ongoing spike protein evidence (increased rouleaux formation) show very clearly that ozone treatments quickly resolve this PSP-associated abnormality seen under the microscope. [28]

Since PSP appears to be the primary, or even sole, culprit in patients suffering from chronic COVID symptomatology, the ability of ozone to resolve such symptomatology indicates that any spike protein present in the body can be obliterated by properly-administered ozone. Since ozone is known to degrade and inactivate intact viruses, it is perfectly logical that it can degrade "pieces" of a virus, such as the spike protein part of the COVID pathogen.

Ultraviolet Blood Irradiation

Direct ultraviolet (UV) irradiation without involving blood irradiation has been well-established for a very long time to be an ideal way to kill pathogens outside of the body. [29-31] The COVID pathogen has also been shown to be easily inactivated by such irradiation. [32]

The awareness of the impact of direct UV irradiation on pathogens eventually lead to investigating the impact of ultraviolet blood irradiation (UBI) on patients with various infections. UBI proved to be as effective against pathogens inside the body as it was against pathogens outside the body. In a series of 47 early to moderate advanced cases of spinal type polio infection, UBI alone cured all of the cases. Dramatic responses have also been documented for the UBI treatment of acute viral hepatitis and advanced sepsis. Even conditions such as arthritis and asthma have responded well to UBI. [33,34]

UBI has also been shown to increase the content of HP inside the phagocytic white blood cells. This fits well with the concept that all the bio-oxidative therapies ultimately utilize the anti-pathogen properties of HP to resolve an infection. [35]

Hyperbaric Oxygen Therapy

An exceptionally powerful therapy for resolving deep-seated and otherwise non-healing infections, hyperbaric oxygen therapy (HBOT) involves the inhalation of oxygen inside a chamber that is pressurized to between 1.5 to 3.0 times normal atmospheric pressure. In addition to increasing blood and tissue oxygen levels, HBOT also appears to utilize the anti-pathogen properties of HP in killing pathogens and resolving infections. [36]

The expense and limited availability of HBOT around the country is the main limiting factor in its more routine usage. It is always worth remembering that this therapy exists when dealing with life- and limb-threatening infections. No patient should ever have an infected limb amputated before all the bio-oxidative therapies, including HBOT, have been administered.

Persistent Spike Protein Treatment

PSP syndrome following unresolved COVID infection and/or following one or more COVID inoculations is gradually becoming its own pandemic. The massive morbidity and mortality secondary to this syndrome must be vigorously treated whenever encountered, as it does not appear to be a condition that many people can resolve on their own, even over an extended period of time.

Except for the rarest of individuals, one or more bio-oxidative therapies must be included in an optimal treatment protocol. Vitamin C, hydrogen peroxide, ozone, and ultraviolet blood irradiation would be the best initial approaches. If a protocol utilizing the highest doses of vitamin C does not readily resolve the persistent symptoms seen in the PSP syndrome, there should be no hesitation to seek out a qualified healthcare practitioner familiar with the proper administration of ozone. In addition to the resolution of all persistent and chronic symptoms associated with the PSP syndrome, troponin and D-dimer should end up normal, and the most common of inflammation-related blood tests, like CRP, should be at minimal levels inside the laboratory reference range.

A good protocol, only administered with the oversight of a qualified healthcare practitioner, for the PSP syndrome should include:

• Ozone autohemotherapy, followed by
• IV vitamin C (50 to 150 grams daily); or any oral form in the highest doses possible
• IV or oral hydrocortisone (25 to 50 mg) in the IV or with the first oral dose of vitamin C
• Ultraviolet blood irradiation if available
• Hydrogen peroxide nebulization
• Methylene blue, 25 to 50 mg two or three times daily

It is up to the treating practitioner to determine how long the protocol should be administered and/or modified as the patient responds positively.

Proteolytic enzymes that can break down the spike protein should also be added (bromelain, N-acetyl cysteine, nattokinase).

A protocol like this can be used for many conditions, but this one is designed in particular to resolve the PSP syndrome.

(OMNS Contributing Editor Dr. Thomas E. Levy televymd@yahoo.com is board certified in internal medicine and cardiology. He is also an attorney, admitted to the bar in Colorado and in the District of Columbia. The views presented in this article are the author's and not necessarily those of all members of the Orthomolecular Medicine News Service Editorial Review Board.)

References

1. Yonker L, Swank Z, Bartsch Y et al. (2023) Circulating spike protein detected in post-COVID-19 mRNA vaccine myocarditis. Circulation [Online ahead of print] Jan 4. PMID: https://pubmed.ncbi.nlm.nih.gov/36597886

2. Hansen T, Titze U, Kulamadayil-Heidenreich N et al. (2021) First case of postmortem study in a patient vaccinated against SARS-CoV-2. International Journal of Infectious Diseases 107:172-175. PMID: https://pubmed.ncbi.nlm.nih.gov/33872783

3. Ondruschka B, Heinrich F, Lindenmeyer M et al. (2021) Multiorgan tropism of SARS-CoV-2 lineage B.1.1.7. International Journal of Legal Medicine 135:2347-2349. PMID: https://pubmed.ncbi.nlm.nih.gov/34486072

4. Imig J (2022) SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clinical Science 136:431-434. PMID: https://pubmed.ncbi.nlm.nih.gov/35348182

5. Oliver T, Murphy D (1920) Influenzal pneumonia: the intravenous injection of hydrogen peroxide. The Lancet 195:432-433. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)11118-9/fulltext

6. Root R, Metcalf J, Oshino N, Chance B (1975) H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors. The Journal of Clinical Investigation 55:945-955. PMID: https://pubmed.ncbi.nlm.nih.gov/1123431

7. Root R, Metcalf J (1977) H2O2 release from human granulocytes during phagocytosis. Relationship to superoxide anion formation and cellular catabolism of H2O2: studies with normal and cytochalasin B-treated cells. The Journal of Clinical Investigation 60:1266-1279. PMID: https://pubmed.ncbi.nlm.nih.gov/199619

8. Evans R, Currie L, Campbell A (1982) The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. The British Journal of Nutrition 47:473-482. PMID: https://pubmed.ncbi.nlm.nih.gov/7082619

9. Ang A, Pullar J, Currie M, Vissers M (2018) Vitamin C and immune cell function in inflammation and cancer. Biochemical Society Transactions 46:1147-1159. PMID: https://pubmed.ncbi.nlm.nih.gov/30301842

10. Pei Z, Wu K, Li Z et al. (2019) Pharmacologic ascorbate as a pro-drug for hydrogen peroxide release to kill mycobacteria. Biomedicine & Pharmacotherapy 109:2119-2127. PMID: https://pubmed.ncbi.nlm.nih.gov/30551469

11. Besinis A, De Peralta T, Handy R (2014) The antibacterial effects of silver, titanium dioxide and silica dioxide nanoparticles compared to the dental disinfectant chlorhexidine on Streptococcus mutans using a suite of bioassays. Nanotoxicology 8:1-16. PMID: https://pubmed.ncbi.nlm.nih.gov/23092443

12. Carter M, Chapman M, Gabler F, Brandi M (2015) Effect of sulfur dioxide fumigation on survival of foodborne pathogens on table grapes under standard storage temperature. Food Microbiology 49:189-196. PMID: https://pubmed.ncbi.nlm.nih.gov/25846930

13. Shomali M, Opie D, Avasthi T, Trilling A (2015) Nitrogen dioxide sterilization in low-resource environments: a feasibility study. PLoS One 10:e0130043. PMID: https://pubmed.ncbi.nlm.nih.gov/26098905

14. Vo H, Imai T. Ho T et al. (2015) Potential application of high pressure carbon dioxide in treated wastewater and water disinfection: recent overview and further trends. Journal of Environmental Sciences (China) 36:38-47. PMID: https://pubmed.ncbi.nlm.nih.gov/26456604

15. Shirai R, Miura T, Yoshida A et al. (2016) Antimicrobial effect of titanium dioxide after ultraviolet irradiation against periodontal pathogen. Dental Materials Journal 35:511-516. PMID: https://pubmed.ncbi.nlm.nih.gov/27252009

16. Akhlaghi M, Dorost A, Karimyan K et al. (2018) Data for comparison of chlorine dioxide and chlorine disinfection power in a real dairy wastewater effluent. Data in Brief 18:886-890. PMID: https://pubmed.ncbi.nlm.nih.gov/29900255

17. Mayer D, Mithofer A, Glawischnig E et al. (2018) Short-term exposure to nitrogen dioxide provides basal pathogen resistance. Plant Physiology 178:468-487. PMID: https://pubmed.ncbi.nlm.nih.gov/30076223

18. Kontorshchikova K, Belova A, Dudenkova V et al. (2017) The level of hydrogen peroxide in HeLa cells in an ozonated medium. Bulletin of Experimental Biology and Medicine 163:570-573. PMID: https://pubmed.ncbi.nlm.nih.gov/28853083

19. Elvis A, Ekta J (2011) Ozone therapy: a clinical review. Journal of Natural Science, Biology, and Medicine 2:66-70. PMID: https://pubmed.ncbi.nlm.nih.gov/22470237

20. Zheng Z, Dong M, Hu K (2020) A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. Journal of Medical Virology 92:2348-2350. PMID: https://pubmed.ncbi.nlm.nih.gov/32437014

21. Izadi M, Cegolon L, Javanbakht M et al. (2021) Ozone therapy for the treatment of COVID-19 pneumonia: a scoping review. International Immunopharmacology 92:107307. PMID: https://pubmed.ncbi.nlm.nih.gov/33476982

22. Tascini C, Sermann G, Pagotto A et al. (2021) Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Internal and Emergency Medicine 16:669-675. PMID: https://pubmed.ncbi.nlm.nih.gov/33131033

23. Budi D, Rofananda I, Pratama N et al. (2022) Ozone as an adjuvant therapy for COVID-19: a systematic review and meta-analysis. International Immunopharmacology 110:109014. PMID: https://pubmed.ncbi.nlm.nih.gov/35803132

24. Franzini M, Valdenassi L, Ricevuti G et al. (2020) Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. International Immunopharmacology 88:106879. PMID: https://pubmed.ncbi.nlm.nih.gov/32795898

25. Chirumbolo S, Varesi A, Franzini M et al. (2022) The mito-hormetic mechanisms of ozone in the clearance of SARS-Co-V2 and in the COVID-19 therapy. Biomedicines 10:2258. PMID: https://pubmed.ncbi.nlm.nih.gov/36140358

26. Lopez-Leon S, Wagman-Ostrosky T, Perelman C et al. (2021) More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Reports 11:16144. PMID: https://pubmed.ncbi.nlm.nih.gov/34373540

27. Tirelli U, Franzini M, Valdenassi L et al. (2021) Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy-preliminary results on 100 patients. European Review for Medical and Pharmacological Sciences 25:5871-5875. PMID: https://pubmed.ncbi.nlm.nih.gov/34604980

28. Levy T (2021) http://orthomolecular.org/resources/omns/v17n24.shtml

29. Reed N (2010) The history of ultraviolet germicidal irradiation for air disinfection. Public Health Reports 125:15-27. PMID: https://pubmed.ncbi.nlm.nih.gov/20402193

30. Welch D, Buonanno M, Grilj V et al. (2018) Far-UVC light: a new tool to control the spread of airborne-mediated microbial diseases. Scientific Reports 8:2752. PMID: https://pubmed.ncbi.nlm.nih.gov/29426899

31. Yang J, Wu U, Tai H, Sheng W (2019) Effectiveness of an ultraviolet-C disinfection system for reduction of healthcare-associated pathogens. Journal of Microbiology, Immunology, and Infection 52:487-493. PMID: https://pubmed.ncbi.nlm.nih.gov/28951015

32. Heilingloh C, Aufderhorst U, Schipper L et al. (2020) Susceptibility of SARS-CoV-2 to UV irradiation. American Journal of Infection Control 48:1273-1275. PMID: https://pubmed.ncbi.nlm.nih.gov/32763344

33. Rowen R (1996) Ultraviolet blood irradiation therapy (photo-oxidation), the cure that time forgot. International Journal of Biosocial and Medical Research 14:115-132. https://www.drmichaelschoenwalder.com/wp-content/uploads/2020/12/Ultraviolet-Blood-Irradiation-Therapy-Photo-Oxidation-The-Cure-That-Time-Forgot.pdf

34. Hamblin M (2017) Ultraviolet blood irradiation of blood: "The cure that time forgot"? Advances in Experimental Medicine and Biology 996:295-309. PMID: https://pubmed.ncbi.nlm.nih.gov/29124710

35. Boretti A, Banik B, Castelletto S (2021) Use of ultraviolet blood irradiation against viral infections. Clinical Reviews in Allergy & Immunology 60:259-270. PMID: https://pubmed.ncbi.nlm.nih.gov/33026601

36. Hink J, Jansen E (2001) Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Medical Hypotheses 57:764-769. PMID: https://pubmed.ncbi.nlm.nih.gov/11918444

Nutritional Medicine is Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Find a Doctor

To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Ilyès Baghli, M.D. (Algeria)
Barry Breger, M.D. (Canada)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Ian Dettman, Ph.D. (Australia)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Gary S. Goldman, Ph.D. (USA)
Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Claus Hancke, MD, FACAM (Denmark)
Patrick Holford, BSc (United Kingdom)
Ron Hunninghake, M.D. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Dwight Kalita, Ph.D. (USA)
Felix I. D. Konotey-Ahulu, MD, FRCP, DTMH (Ghana)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Pedro Gonzalez Lombana, MD, MsC, PhD (Colombia)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Juan Manuel Martinez, M.D. (Colombia)
Mignonne Mary, M.D. (USA)
Joseph Mercola, D.O. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Tahar Naili, M.D. (Algeria)
Zhiyong Peng, M.D. (China)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas N. Seyfried, Ph.D. (USA)
Han Ping Shi, M.D., Ph.D. (China)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Jagan Nathan Vamanan, M.D. (India)

Andrew W. Saul, Ph.D. (USA), Editor-In-Chief
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Editor, German Edition: Bernhard Welker, M.D. (Germany)
Contributing Editor: Thomas E. Levy, M.D., J.D. (USA)
Contributing Editor: Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Contributing Editor: W. Todd Penberthy, Ph.D. (USA)
Contributing Editor: Ken Walker, M.D. (Canada)
Contributing Editor: Michael Passwater (USA)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Associate Technology Editor: Robert C. Kennedy, M.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: drsaul@doctoryourself.com OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html

To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html